Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma

Xenobiotica

Volumn 30, Issue 10, 2000, Pages 993-1003

  Oikawa, K ^a   Watanabe, T ^a   Miyamoto, I ^a   Higuchi, S ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; COMPLEMENT COMPONENT C1S INHIBITOR; PAMITEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; COMPLEX FORMATION; COVALENT BOND; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN;

EID: 0033711170     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250050200140     Document Type: Article

References (26)

1. 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism
2. Enzyme-linked immunosorbent assays for plasminogen activator
3. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation
4. Inhibition of the human tissue plasminogen activator in plasma from different species
5. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA
6. Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity
7. Metabolic fate of recombinant human tissue plasminogen activator (rt-PA) (1)
8. Biochemical and pharmacokinetics properties of pamiteplase, a novel fibrinolytic agent
9. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator
10. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis
11. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis
12. Gene construction and large scale production of a novel fibrinolytic agent (pamiteplase) in CHO cells
13. Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men
14. Metabolic fate of SM-9527 in rats
15. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: No evidence for a specific inhibitor
16. 2-plasmin inhibitor from human plasma
17. Pharmacokinetics of YM866 and t-PA after intravenous administration to rats and dogs
18. Metabolic fate of YM866, a novel fibrinolytic agent
19. Metabolic fate of TD-2061(I)
20. A sensitive ELISA for human tissue-type plasminogen activator applicable to the study of acute release from cultured human endothelial cells
21. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers
22. Circadian fluctuation of plasmatic plasminogen activator and its inhibitor PAI-1 of Japanese adults
23. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects
24. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma
25. An improved fibrin plate method for the assay of plasminogen
26. t-PA activity assay method in blood sample using dipstick coated with a monoclonal antibody SP-322